Yao Jie J, Jurgensmeier Kevin, Whitson Anastasia J, Pottinger Paul S, Matsen Frederick A, Hsu Jason E
Department of Orthopaedic Surgery and Sports Medicine, University of Washington, Seattle, Washington.
School of Medicine, University of Washington, Seattle, Washington.
J Bone Joint Surg Am. 2022 Mar 2;104(5):421-429. doi: 10.2106/JBJS.20.02263.
Following revision shoulder arthroplasty, postoperative antibiotics are selected before the results of intraoperative cultures become available. We determined infection-free survival, revision-free survival, complications, and patient-reported outcomes for patients selected to receive oral or intravenous (IV) antibiotics after revision arthroplasty.
This study included 92 patients who had revision shoulder arthroplasty. IV antibiotics were administered if the surgeon had a high index of suspicion for infection, and oral antibiotics were given if there was a low suspicion. Antibiotic therapy was modified based on intraoperative culture results. Patient-reported outcomes and adverse events were documented at a mean of 4.1 years.
In selecting antibiotic therapy, surgeons correctly predicted the presence or absence of multiple positive cultures of specimens from the revision surgery in 72% of the 92 cases. Subsequent re-revision surgery was required in 17 (18%) of the patients; 8 of these 17 patients had ≥2 positive cultures at re-revision. Patients who initially received IV antibiotics and those who initially received oral antibiotics had similar revision-free (p = 0.202) and infection-free (p = 0.155) survivorship. Patients requiring a change from oral to IV antibiotics based on positive cultures had similar survivorship compared with those initially treated with IV antibiotics. The IV and oral antibiotic groups had similar postoperative Simple Shoulder Test (SST), American Shoulder and Elbow Surgeons (ASES), and satisfaction scores. Patients receiving IV antibiotics had a higher rate of antibiotic-related adverse events.
Post-revision antibiotic therapy was associated with an infection-free survival rate of 91% at a mean of >4 years of follow-up. Infection-free survival, revision-free survival, and patient-reported outcomes were similar in high-risk patients placed on IV antibiotics and low-risk patients placed on oral antibiotics. Further study is needed to define the indications for IV or oral antibiotics after revision arthroplasty.
Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
在翻修肩关节置换术后,在术中培养结果出来之前就选择术后抗生素。我们确定了翻修关节置换术后选择接受口服或静脉注射(IV)抗生素治疗的患者的无感染生存率、无翻修生存率、并发症以及患者报告的结局。
本研究纳入了92例行翻修肩关节置换术的患者。如果外科医生高度怀疑感染,则给予静脉注射抗生素;如果怀疑程度低,则给予口服抗生素。根据术中培养结果调整抗生素治疗。在平均4.1年时记录患者报告的结局和不良事件。
在选择抗生素治疗时,外科医生在92例病例中的72%正确预测了翻修手术标本多次阳性培养的存在与否。17例(18%)患者随后需要再次翻修手术;这17例患者中有8例在再次翻修时有≥2次阳性培养。最初接受静脉注射抗生素的患者和最初接受口服抗生素的患者的无翻修生存率(p = 0.202)和无感染生存率(p = 0.155)相似。根据阳性培养结果需要从口服抗生素改为静脉注射抗生素的患者与最初接受静脉注射抗生素治疗的患者生存率相似。静脉注射和口服抗生素组的术后简易肩关节测试(SST)、美国肩肘外科医生协会(ASES)评分及满意度相似。接受静脉注射抗生素的患者抗生素相关不良事件发生率更高。
在平均随访>4年时,翻修术后抗生素治疗的无感染生存率为91%。接受静脉注射抗生素的高危患者和接受口服抗生素的低危患者的无感染生存率、无翻修生存率以及患者报告的结局相似。需要进一步研究来确定翻修关节置换术后静脉注射或口服抗生素的适应证。
治疗性IV级。有关证据水平的完整描述,请参阅作者指南。